Course Overview



This course will be held again on
April 23 - 27, 2019.

Information contained in this site is for the 2018 program.
Information for the 2019 program not yet available.

State-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases

This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis and treatment of infectious diseases. Updates, best practices and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven:

  • State-of-the-art approaches to common infections
  • New strategies for treating highly resistant bacterial infections
  • Clinical approaches to complex, rare, "don't-miss" infections
  • New and emerging infectious diseases
  • Update on antifungal diagnostics and therapy
  • Optimal management of Staph aureus
  • Infections in persons with substance use disorders
  • What’s new in HIV management
  • Hep C treatment workshop 
  • Live New England Journal of Medicine Clinicopathologic Conference (CPC)
  • Musculoskeletal infectious diseases 
  • Strategies for optimal decision-making in the prevention, diagnosis and treatment of infectious diseases

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.  

Highlights of the 2018 Program

Expanded Case-Based and Problem-Solving Education 

The 2018 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions in larger sessions as well as one-on-one with the national experts who will be providing updates at this event.

Treating Highly Resistant Bacterial Infections, including:

  • MRSA and vancomycin-intermediate Staph aureus (VISA)
  • Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
  • Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
  • Vancomycin-resistant enterococci (VRE) 

Common Infectious Diseases: Updates in Prevention, Diagnosis and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

  • Infections in immunocompromised hosts
  • Infections in pregnancy, including Zika
  • Infections in persons with substance use disorders
  • Infections of travelers
  • Systemic fungal infections
  • Native and device-related orthopedic infections
  • Ear, nose and throat (ENT) and eye infections
  • Bronchiectasis and pneumonia
  • Native and device-related central nervous system (CNS) infections
  • HIV and its infectious and noninfectious complications
  • PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
  • Sexually transmitted infections
  • Hepatitis C monoinfection and coinfection
  • Tick and mosquito-borne infections and zoonoses
  • Vaccination
  • Clostridium difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

  • Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
  • Infections in travelers and immigrants
  • Zoonoses—the old and the new
  • Re-emergence of vaccine-preventable diseases 
  • Non-tuberculous (“atypical”) mycobacteria including Mycobacterium chimaera
  • Candida auris 

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

  • Selecting the right antimicrobial
  • Utilizing newer diagnostic tests
  • Diagnosing low-probability but high-impact infections
  • Rapidly detecting life-threatening infections
  • Determining when and how long to hospitalize in the treatment of infectious diseases
  • The outpatient transition: IV or oral?
  • Optimizing empiric antimicrobial therapy: what to start, when to narrow or when to stop  

Safety, Quality, and Practice Improvement

Special sessions on quality and safety in the field, and on the value added by ID specialists: 

  • Antimicrobial stewardship
  • Infection control
  • Early inpatient ID consultations to reduce mortality, length of stay, and cost
  • Outpatient Parenteral Antibiotic Therapy (OPAT): best practices in program design and operation
  • ID for hospital medicine practitioners


State-of-the-Art Treatment of Hepatitis C
Friday, May 4, 2:00 - 4:30 pm

This new program provides a special and timely opportunity to learn about recent important changes in Hepatitis C care.

Highlights of this practical, small group, interactive educational experience include:

  • A comprehensive review of the new medications for HCV
  • Selecting an optimal treatment regimen
  • Updates on drug interactions
  • Best practices for patient assessment, monitoring, side-effect management, and follow-up
  • Optimal treatment of patients with HIV/HCV coinfection
  • Guidance for managing persons with substance use disorders

Led by Massachusetts General Hospital/Harvard Medical School’s Arthur Kim, MD, a nationally and internationally recognized specialist in Hepatitis C, participants will leave with specific recommendations to improve the clinical care of people infected with HCV.